News

Investigators concluded that the findings are suggestive of a link between faster cognitive decline, especially frontal lobe dysfunction, in patients with Parkinson who develop levodopa-induced dyskinesia.

A simple screening test may help identify those at risk.

The PDUFA date for the novel oral fumarate has been set for the fourth quarter of 2019. If approved, Biogen plans to commercialize the product under the trade name Vumerity.

The investigators wrote that these findings are suggestive of a superior effect of natalizumab and rituximab compared with fingolimod in suppressing further disease activity in patients with RRMS who switched from interferon or glatiramer acetate due to breakthrough disease.

The findings suggested that a patient’s likelihood of taking medications systematically decreased as the probability of potential AEs occurring increased or the efficacy of treatment decreased.

Neurology News Network for the week of February 23, 2019.

If approved, eptinezumab, an Alder Biopharmaceuticals product, would become the fourth member of the CGRP class, and the only member available for quarterly infusions.

In a cohort study of 592 patients with MS, the findings were suggestive that real-world escalation approaches may be inadequate to prevent unfavorable long-term outcomes.

Over the past several years, scientific teams have developed investigational methods for delivering a gene to correct a mutation in the DMD gene which causes DMD by creating dysfunction in a patient’s dystrophin production.

The professor of neurology and pediatrics at Columbia University Irving Medical Center spoke about the success of the small molecule in older infants with SMA, and about what she’s looking forward to in the future of SMA treatment.

More recently, investigators have discovered that catechol-O-methyltransferase inhibitors can prolong the effects of levodopa, thereby limiting the off-time phenomenon.

AED use was not significantly associated with dementia risk in patients followed by general practitioners and neuropsychiatrists, however, the potential harmful effects of levetiracetam generic brands on cognition should be further investigated.

A patient believes excessive gaming is his way to mask his depression, but it may be a result of something else.

The investigational drug candidate, formerly known as CK-2127107, is the subject of the phase 2b FORTITUDE-ALS trial, which is assessing the effect of reldesemtiv compared with placebo on respiratory function and additional measures of skeletal muscle function.